Noor Siddiqui founded Orchid so people could “have healthy babies.” Now she’s using the company’s gene technology on herself—and talking about it for the first time.
Did you read what she was claiming it could do with a minuscule sample and a fancy algorithm? That is exactly the same claim as Theranos.
Comparing Theranos’ claims with the state of the art at the time should’ve revealed that they were implausible: some blood tests genuinely require a substantial amount of blood in order to properly process and separate and look for a statistically valid measurement of something about that blood, because blood isn’t homogenous and the act of drawing blood actually changes it.
Comparing this embryo screening claim with the state of the art is comparatively less of a leap. It’s just genetic sequencing, which has already advanced to the point where an entire genome can be sequenced with a tiny number of cells (including some single-cell sequencing techniques that are more complex and less reliable), plus actual correlative analysis of specific genes, plugging into existing research (the way 23 and me can do it for like $20).
I have some skepticism, but this business’s model really seems to be assembling steps that others have already established, and not inventing anything new.
Comparing Theranos’ claims with the state of the art at the time should’ve revealed that they were implausible: some blood tests genuinely require a substantial amount of blood in order to properly process and separate and look for a statistically valid measurement of something about that blood, because blood isn’t homogenous and the act of drawing blood actually changes it.
Comparing this embryo screening claim with the state of the art is comparatively less of a leap. It’s just genetic sequencing, which has already advanced to the point where an entire genome can be sequenced with a tiny number of cells (including some single-cell sequencing techniques that are more complex and less reliable), plus actual correlative analysis of specific genes, plugging into existing research (the way 23 and me can do it for like $20).
I have some skepticism, but this business’s model really seems to be assembling steps that others have already established, and not inventing anything new.